- Robust, Unbiased and Affordable 4D-Proteomics™ for
Highest-Specificity Protein IDs & Quant Enables High-Fidelity
Large-Scale Plasma Proteomics
- Typical Sequence Coverage >10 Peptides/protein and
>100k Peptides per Cell-Line Proteome Ushers in HiFi Proteomics
with High Isoform Specificity
- Novel diagonal-PASEF® methods for immunopeptidomics
and PTM characterization
- Achieving one-hundred-dollar high-fidelity plasma
proteomics with PreOmics ENRICH™ and robust timsTOF HT
acquisition for deep, unbiased plasma proteomics at scale with
99% specificity (1% FDR) In parallel, Biognosys introduces
discovery services with P2 enrichment and
Spectronaut® 19 for ultra-deep plasma proteomics with 7k or 9k
identified proteins; optional integration of Alamar Bio
ultra-high sensitivity NULISA® inflammation and CNS
multiplex panels
- Glyco-PASEF® acquisition, ENRICHplus and
GlycoScape enable high-sensitivity plasma glycopeptide
analysis on timsTOF Ultra 2
- ML-enhanced TIMSrescore™ increases immunopeptidomics and
PTM IDs; enables ultra-high-fidelity metaproteomics at 0.1%
FDR (99.9% specificity)
- Advancing 4D-Multiomics by combining proteomic,
lipidomic and metabolomic insights
At the 23rd Human Proteome Organization World Congress, Bruker
Corporation (Nasdaq: BRKR) announces advances in deep, unbiased and
high-sensitivity 4D-Proteomics for robust, high- fidelity,
large-scale studies - avoiding inherent cross-talk of affinity
high-plex technologies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20241021537973/en/
Bruker's timsTOF Ultra 2 Mass
Spectrometer (Graphic: Business Wire)
A. Enhanced specificity and proteome coverage using
diagonal-PASEF
Leveraging scanning quadrupole and trapped ion mobility
spectrometry (TIMS), diagonal-PASEF was introduced in 2023
by key collaborators Dr. Matthias Mann (Max Planck Institute,
Martinsried) and Dr. Stefan Tenzer (University of Mainz) to develop
synchro-PASEF and midia-PASEF, respectively. Bruker
and its partners now support all variants via Spectronaut 19,
DIA-NN 1.9, MaxQuant 2.6.3, and midiaID.
Synchro-PASEF allows high-throughput acquisitions, while
ensuring quantitative precision due to better sampling of ions,
short cycle times, and up to 3-fold improved signal strength.
midia-PASEF offers higher-confidence immunopeptidomics
and PTMs by extracting DDA-like spectra for de novo sequencing, and
searches against very large databases.
Dr. Jarrod Marto, professor at Dana-Farber Cancer
Institute, Harvard Medical School, participated in the midia-PASEF
early-access program, and commented: “My lab leverages the timsTOF
to understand how genomic alterations or small molecule probes
manifest throughout the functional proteome. Our assessment is very
positive, and we are now exploring the potential of midia-PASEF for
quantitative analysis of post-translational modifications, as well
as of MHC-associated peptides.”
B. Achievement of One-hundred Dollar Deep, High-accuracy
Plasma Proteome
Bruker spearheads deep, unbiased plasma proteome profiling with
throughput, high peptide fidelity, and at enabling economics for
large-scale studies. Together, PreOmics ENRICH-iST or ENRICHplus
methods, robust and accurate (99% specificity, 1% FDR) protein IDs
on timsTOF HT with Spectronaut 19, enable deep,
species-independent, high-fidelity plasma proteomics at scale -
with cost as low as $100 per plasma sample [PreOmics].
Biopharma can access ultra-deep plasma proteome discovery with
depth up to 7k proteins, or up to 9k at lower throughput, via
research services offered by Biognosys, or by licensing proprietary
P2 ultra-deep plasma enrichment for in-house use [Biognosys].
C. Introducing High-Sensitivity Plasma Glycopeptide Analysis
on timsTOF Ultra 2
Bruker’s glyco-PASEF® for glycoproteomics has been
optimized for the ultra-high sensitivity timsTOF Ultra 2 and human
plasma samples. The new method incorporates ENRICHplus,
resulting in a doubling of glycopeptides identified, and
GlycoScape® data-base-independent software for integrated,
deep glycobiology analysis.
D. Increased Peptide and Protein Identifications and
ML-enhanced TIMSrescore
The timsTOF platform now routinely identifies much more than
100,000 peptides from human cell line proteomics with less than 1
µg loading in 20 minutes. High sequence coverage of typically
>10 peptides/protein is critical for confident ID and quant,
high isomer specificity, for detecting PTMs, as well as for
immunopeptidomics and metaproteomics.
Bruker also is introducing TIMSrescore, developed with
Dr. Lennart Martens’ team at the University of Ghent. Using
ML for timsTOF collision cross-sections, retention time and
fragment intensity, TIMSrescore increases high-confidence peptide
IDs for dda-PASEF, relevant for PTMs and metaproteomics, where
highest stringency (99.9% specificity at 0.1% FDR) is critical to
distinguish highly similar proteins across myriads of microbial
species.
Dr. Lennart Martens, Associate Director of Bioinformatics
at the University of Ghent Center for Medical Biotechnology,
stated: "My team and I are pleased with the enthusiastic uptake of
TIMS2Rescore by our proteomics community. Through integration
within Bruker ProteoScape software, we expand MS2rescore to timsTOF
users, allowing our ML-based informatics to maximize the value of
4D-Proteomics.”
E. Introducing Multiomics Visualization and Insights for
Proteomics and Metabolomics
Bruker ProteoScape™ now offers visualization and
statistical analysis of 4D-Multiomics data from
MetaboScape® for metabolomics and lipidomics. This enables
dimensional reduction (such as PCA, LDA or t-SNE) and differential
analysis, as well as intuitive visualizations, e.g., via
interactive multiomics Volcano plots.
Dr. Roman Fischer, Associate Professor at University of Oxford,
commented: “We utilize our timsTOFs for proteomics and lipidomics.
The capabilities of ProteoScape and MetaboScape are impressive for
real-time analysis to translate data into biological insights. It’s
fantastic that Bruker now integrates both worlds with interactive
multiomics visualization and statistical analysis.”
About Bruker Corporation – Leader of the Post-Genomic Era
(Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough
post-genomic discoveries and develop new applications that improve
the quality of human life. Bruker’s high performance scientific
instruments and high value analytical and diagnostic solutions
enable scientists to explore life and materials at molecular,
cellular, and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, improved productivity,
and customer success in post-genomic life science molecular and
cell biology research, in applied and biopharma applications, in
microscopy and nanoanalysis, as well as in industrial and cleantech
research, and next-gen semiconductor metrology in support of AI.
Bruker offers differentiated, high-value life science and
diagnostics systems and solutions in preclinical imaging, clinical
phenomics research, proteomics and multiomics, spatial and
single-cell biology, functional structural and condensate biology,
as well as in clinical microbiology and molecular diagnostics. For
more information, please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241021537973/en/
Media Petra Scheffer Bruker Daltonics Marketing
Communications T: +49 (421) 2205-2843 E:
petra.scheffer@bruker.com
Investor Relations Joe Kostka Associate Director,
Investor Relations T: +1 (978) 313-5800 E:
Investor.Relations@bruker.com
Grafico Azioni Bruker (NASDAQ:BRKR)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Bruker (NASDAQ:BRKR)
Storico
Da Gen 2024 a Gen 2025
